Wall Street Zen Upgrades Nutex Health (NASDAQ:NUTX) to “Strong-Buy”

Nutex Health (NASDAQ:NUTX) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Friday.

A number of other research analysts also recently weighed in on NUTX. Maxim Group set a $205.00 target price on shares of Nutex Health and gave the company a “buy” rating in a research report on Tuesday, August 26th. Weiss Ratings upgraded Nutex Health from a “sell (d)” rating to a “hold (c)” rating in a report on Tuesday. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $252.50.

Nutex Health Trading Up 4.0%

NASDAQ NUTX opened at $117.28 on Friday. Nutex Health has a 12 month low of $28.12 and a 12 month high of $184.27. The stock has a 50-day simple moving average of $112.98 and a 200 day simple moving average of $113.36. The company has a current ratio of 2.27, a quick ratio of 2.26 and a debt-to-equity ratio of 1.02. The company has a market capitalization of $829.40 million, a PE ratio of 9.86 and a beta of -0.23.

Nutex Health (NASDAQ:NUTX) last posted its earnings results on Tuesday, November 18th. The company reported $7.76 earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.43) by $13.19. The company had revenue of $243.99 million during the quarter, compared to analyst estimates of $221.93 million. Nutex Health had a return on equity of 42.08% and a net margin of 10.76%.

Insider Buying and Selling

In other Nutex Health news, CFO Jon Christian Bates purchased 750 shares of the stock in a transaction on Tuesday, November 25th. The shares were purchased at an average price of $136.71 per share, with a total value of $102,532.50. Following the completion of the transaction, the chief financial officer directly owned 5,638 shares in the company, valued at $770,770.98. This represents a 15.34% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 36.92% of the company’s stock.

Institutional Investors Weigh In On Nutex Health

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Pertento Partners LLP acquired a new position in Nutex Health in the 3rd quarter valued at $27,940,000. Topline Capital Management LLC increased its stake in Nutex Health by 80.0% in the third quarter. Topline Capital Management LLC now owns 556,567 shares of the company’s stock valued at $57,505,000 after acquiring an additional 247,436 shares during the last quarter. Marshall Wace LLP increased its stake in Nutex Health by 333.4% in the second quarter. Marshall Wace LLP now owns 94,548 shares of the company’s stock valued at $11,770,000 after acquiring an additional 72,734 shares during the last quarter. Millennium Management LLC raised its position in Nutex Health by 191.1% during the third quarter. Millennium Management LLC now owns 93,396 shares of the company’s stock valued at $9,650,000 after purchasing an additional 61,308 shares in the last quarter. Finally, Divisadero Street Capital Management LP bought a new stake in shares of Nutex Health during the 2nd quarter worth $7,481,000. Institutional investors and hedge funds own 5.32% of the company’s stock.

About Nutex Health

Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.